ScholarLens Back to search
2007•The Lancet Infectious DiseasesRequires access

Is it safe to switch between efavirenz and nevirapine in the event of toxicity?

Ushma Mehta, Gary Maartens

Open publisher page 46 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 46 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Nevirapine, Efavirenz, Rash, Reverse-transcriptase inhibitor, Medicine, Adverse effect, Pharmacology, Adverse drug reaction

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Is it safe to switch between efavirenz and nevirapine in the event of toxicity? — Research Paper | ScholarLens